Trajan Wealth LLC Buys 1,675 Shares of Amgen Inc. (NASDAQ:AMGN)

Trajan Wealth LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 11.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,596 shares of the medical research company's stock after buying an additional 1,675 shares during the period. Trajan Wealth LLC's holdings in Amgen were worth $4,326,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter worth about $25,000. Ritter Daniher Financial Advisory LLC DE grew its position in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in Amgen during the 4th quarter worth $34,000. Atala Financial Inc acquired a new position in Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the 4th quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP David M. Reese sold 8,711 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the transaction, the executive vice president now directly owns 62,147 shares in the company, valued at approximately $18,222,743.34. This trade represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company's stock.

Amgen Trading Up 0.7 %

Shares of AMGN stock traded up $1.94 during trading hours on Thursday, hitting $279.84. 2,259,859 shares of the company's stock traded hands, compared to its average volume of 2,788,100. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a market cap of $150.46 billion, a PE ratio of 37.06, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The stock's 50 day simple moving average is $301.98 and its 200 day simple moving average is $293.34.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Analysts Set New Price Targets

A number of research analysts recently commented on AMGN shares. Cantor Fitzgerald assumed coverage on Amgen in a research report on Tuesday. They issued a "neutral" rating and a $305.00 price target on the stock. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Morgan Stanley upped their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 9th. UBS Group increased their price target on shares of Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Finally, Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $310.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.